Neuropathologic Changes in People With Essential Tremor With Dementia
- 25 November 2025
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (10) , e214310
Abstract
Prospective cohort studies have demonstrated elevated risks of incident dementia in patients with essential tremor (ET). The explanation for this enhanced risk of dementia in ET is unknown. We aimed to elucidate the underlying neuropathologic features of ET-dementia. In a 10-year, prospective cohort study of cognition in ET, we followed participants with detailed neuropsychological testing (assessing 5 primary domains) and assigned cognitive diagnoses (normal cognition, mild cognitive impairment [MCI], or dementia) by expert consensus; brains were collected at death. Participants resided in 43 US states. The detailed neuropathologic assessment included a Braak neurofibrillary tangle stage, Braak Lewy pathology stage, Thal β-amyloid score, and neuritic plaque score. The overall level of Alzheimer disease neuropathologic changes (ADNCs) was reported using the "ABC" scale. Other tauopathies and comorbid cerebrovascular pathologies were diagnosed. During statistical comparisons, we stratified each of the above neuropathologic features into 2 categories: high vs low. We examined how neuropathologic findings mapped onto cognitive diagnoses. The 381 participants yielded 86 brains (mean age at death 90.1 years, 55.8% female). Participants with ET-dementia (n = 40) had higher odds of having severe AD-type pathologies than ET-NC (n = 30): advanced Braak AD stage odds ratio (OR) = 22.8, Thal score OR = 8.0, Consortium to Establish a Registry for Alzheimer Disease score OR = 5.7, and ADNC score OR = 21.1; cerebral amyloid angiopathy scores were also higher (OR = 4.3) (all p ≤ 0.01). Participants with ET-MCI (n = 16) demonstrated intermediate neuropathology, with greater odds of higher Braak AD stages than those with ET-NC (OR = 8.0, p = 0.009). Other neuropathologies were similar across cognitive groups. Our neuropathologic description of ET-dementia shows that, in this sample of 40 participants with ET-dementia, Alzheimer pathology is the prime driver of marked cognitive impairment in ET. Further studies are needed to refine our understanding of the nature of tau aggregation in ET and the extent to which this is similar to or diverges from that seen in AD. One implication of the current finding, which is a more direct link between ET and AD, is that this opens the door to blood-based biomarker testing in individuals with ET who are experiencing cognitive difficulties.Keywords
This publication has 50 references indexed in Scilit:
- Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's diseaseAlzheimer's & Dementia, 2024
- Evaluating the updated LATE‐NC staging criteria using data from NACCAlzheimer's & Dementia, 2024
- Prevalence of and Annual Conversion Rates to Mild Cognitive Impairment and Dementia: Prospective, Longitudinal Study of an Essential Tremor CohortAnnals of Neurology, 2024
- Pathologically based criteria to distinguish essential tremor from controls: analyses of the human cerebellumAnnals of Clinical and Translational Neurology, 2024
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- Risk of incident dementia in essential tremor: A population‐based studyMovement Disorders, 2007
- Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistryActa Neuropathologica, 2006
- Comparison of clinical vs. electrophysiological methods of diagnosing of essential tremorMovement Disorders, 2001
- Reliability between two observers using a protocol for diagnosing essential tremorMovement Disorders, 1998
- Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological studyAnnals of Neurology, 1991